{
    "pmcid": "9479348",
    "qa_pairs": {
        "What is the IC50 value of C5G2 for inhibiting ACE2 binding to the RBD?": [
            "3.7 nM",
            "5.2 nM",
            "2.9 nM",
            "4.5 nM"
        ],
        "What is the name of the synthetic nanobody library used in the study for developing SARS-CoV-2 nanobody binders?": [
            "AUAM synthetic nanobody library (ASyNAL)",
            "Camelid synthetic nanobody library (CSyNAL)",
            "Randomized synthetic nanobody library (RSyNAL)",
            "Spike-targeted synthetic nanobody library (SSyNAL)"
        ],
        "What unique feature of C5G2's binding mode allows it to maintain efficacy across multiple variants?": [
            "Binding to a conserved region of the RBD primarily through its CDR3 loop",
            "Binding to a variable region of the RBD primarily through its CDR1 loop",
            "Binding to a conserved region of the NTD primarily through its CDR2 loop",
            "Binding to a variable region of the NTD primarily through its CDR3 loop"
        ],
        "Which SARS-CoV-2 variant did C5G2 not demonstrate broad-spectrum neutralizing activity against?": [
            "Delta",
            "Alpha",
            "Beta",
            "Gamma"
        ],
        "Which nanobody was identified as capable of competing with ACE2 for binding to the RBD in the study?": [
            "C5",
            "C7",
            "C3",
            "C9"
        ]
    }
}